Lineage Cell Therapeutics enters $14M registered direct offering at $1.04/share

Lineage Cell Therapeutics, Inc.

Sale of 13,461,540 common shares at $1.04 each; gross proceeds of $14.0M.
Broadwood Partners (affiliated with director Neal Bradsher) to buy 6,730,770 shares.
Director Don M. Bailey to buy approximately 100,000 shares in the offering.
Closing expected on or about February 8, 2024, subject to customary conditions.
Proceeds to fund clinical trials, R&D, G&A, and working capital.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Lineage Cell Therapeutics, Inc. entered into purchase agreement with certain investors valued at $14.0 million (effective 2024-02-06).

Action: entry
Agreement: equity purchase
Counterparty: certain investors
Value: $14.0 million
Effective: 2024-02-06

Exact text from the filing

On February 6, 2024, Lineage Cell Therapeutics, Inc. (the “Company” or “Lineage”) entered into a stock purchase agreement (the “purchase agreement”) with certain investors relating to the purchase and sale in a registered direct offering of an aggregate of 13,461,540 common shares of the Company.

View on SEC.gov

Browse all material agreements →

Lineage Cell Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-005046

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.